Earnings call
Jagsonpal Pharmaceuticals Q2 FY25 earnings call: Jagsonpal Pharmaceuticals Limited is confident of margins of 22% plus for the current year, up from its earlier guidance of 20% plus
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The company is confident of margins of 22% plus for the current year, up from its earlier guidance of 20% plus. The company achieved quarterly sales of ₹747 Mn in Q2FY25, up 29.2% compared to Q2FY 24; its sales for the quarter were ₹75 crores, with growth of 29% over the comparable period; it recorded revenues of ₹74.7 crores in Q2FY25, growth of 29.2%. The company faced hypercompetition in dydrogesterone and significant spurious product availability in its Indomethacin franchise around August/September 2023. The dydrogesterone franchise became Jagsonpal Pharmaceuticals Limited’s largest product within 18 months of launch; Jagsonpal Pharmaceuticals Limited launched Dydrogesterone about 28 or 30 months ago, and it became very big. Cash to EBITDA conversion was over 100%, helping it establish a war chest of almost Rs. 150 crores by March 2024.
The numbers management gave
Results
- The company achieved quarterly sales of ₹747 Mn in Q2FY25, up 29.2% compared to Q2FY 24; its sales for the quarter were ₹75 crores, with growth of 29% over the comparable period; it recorded revenues of ₹74.7 crores in Q2FY25, growth of 29.2%.
Show source
Our sales for the quarter were ₹75 crores with a growth of 29% over comparable period.
- Core business grew 5% over q2 last year and over 33% over its average quarterly performance for the second half last year; a significant part of the company’s growth was on account of the acquired business.
Show source
While a signif icant part of this growth was on account of the acquired business, I am happy to report that our core business is also back on track with growth of 5% over q2 last year and over 33% over average quarterly performance for the second half last year.
- Net profit rose 53% to ₹114 million, yielding a net profit margin of 15.3% in Q2 FY25; its net profit grew by 53% to ₹11.4 crores in Q2FY25, with a net profit margin of 15.3%.
Show source
Our net profit for the quarter grew by 53% to ₹11.4 crores, translating to a net profit margin of 15.3%.
- The company posted revenues of ₹136.1 crores in the first half of FY25, growth of 15.3%.
Show source
For the first half of FY25, we posted revenues of ₹136.1 crores, reflecting a healthy growth of 15.3%.
- Net profit rose 12% to ₹16.8 crores in the first half of FY25, resulting in a net profit margin of 12.3%; growth was slightly lower on account of exceptional accounting of Rs. 3.3 crores in q1 towards acquisition-related costs.
Show source
Our net profit also saw a 12% rise to ₹ 16.8 crores, resulting in a net profit margin of 12.3%.
- Gross margins in the business are about 65%, if not more.
Show source
Our gross margins in the business are fairly decent at about 65%, if not more.
Show 10 more statements
Results
- About INR14 crores of Jagsonpal Pharmaceuticals Limited’s ₹74.7 crores sales were contributed by the Yash Pharma related division in Q2FY25.
Show source
About INR14 crores out of that 74.7 is contributed by the Yash Pharma related division.
- Organic growth was between 2% and 2.5% in the first half, largely driven by 5% growth in Q2 after Q1 was almost flat.
Show source
Manish Gupta: In the first half, our organic growth is 2%, between 2% and 2.5%.
- The company recorded revenues of ₹74.7 crores in Q2FY25, growth of 29.2%. Replaced by a later filing.
- Operating margins before accounting for ESOP costs expanded by 290 basis points to 24.6% in Q2FY25, driving a 46.6% increase in operating EBITDA to ₹18.4 crores. Replaced by a later filing.
- Operating margins, pre-ESOP, expanded by 130 basis points to 22.8% in the first half of FY25, leading to a 22.4% increase in operating EBITDA to ₹31.1 crores. Replaced by a later filing.
Money and capital
- Cash to EBITDA conversion was over 100%, helping it establish a war chest of almost Rs. 150 crores by March 2024.
Show source
Our efficient management of working capital led to cash to EBITDA conversion of over 100%, helped us establish significant war chest of almost Rs. 150 crores by March 2024.
- Cash balance increased by Rs. 15.8 crores to Rs. 93.4 crores on 30 th September.
Show source
Our business performance supported by strong financial discipline resulted in Rs. 15.8 crores increase in our cash balance which stood at Rs. 93.4 crores on 30 th September.
- Cash to EBITDA conversion was close to 100% or 103% over the last five years.
Show source
In fact, our cash to EBITDA conversion has been close to 100% or 103% over last five years.
- The board approved subdividing Jagsonpal Pharmaceuticals Limited’s equity shares from a face value of ₹5 to ₹2, subject to shareholders’ approval.
Show source
In furtherance to that, the Board at their meeting held on 23 Oct 24, have approved a Page 3of 19 Jagsonpal Pharmaceutical Limited October 24, 202 4 stock split to change the face value of our equity shares from Rs. 5/ - to Rs. 2/-, with a view to create more liquidity in the stock and make it more investor friendly.
- The company will use its cash and future cash generation only for inorganic strategies.
Show source
So all of this cash and whatever we generate even going forward will be used for inorganic strategies only.
What it expects ahead
What management expects
- The company is confident of margins of 22% plus for the current year, up from its earlier guidance of 20% plus.
Show source
Now, we are confident of 22% plus for sure.
- The company is fairly confident it will improve its H1 margins in the current year and deliver 100 bps to 150 bps, if not more, of margin expansion year on year over the next three years.
Show source
But we are fairly confident on improving our H1 margins in the current year for sure and delivering a 100 bps to 150 bps, if not more, margin expansion year on year over the next three years.
- Sales growth guidance of 12% to 14% will lead to margin expansion because costs do not increase in proportion to sales.
Show source
And therefore, our growth in sales, which is where we are guiding towards 12 % to 14%, will certainly lead to margin expansion as our costs do not go in proportion to that.
- 12% to 14% growth guidance is for pure organic growth; any inorganic growth is additional and cannot be predicted.
Show source
And clearly the 12% to 14% guidance that we have given is the pure organic growth.
- The company expects its guided 12% to 14% top-line growth over the medium term to come equally from volume increase, price increase and new products, with each contributing 3% to 5%.
Show source
So I believe the 12- 14% growth that we have been guiding to will be combination of the three with equal weightage for all of them.
- The company expects to be closer to 30% EBITDA margin, if not exceeding that level, in 3 years.
Show source
But I believe in 3 years, we should be closer to 30%, if not breaching the mark.
Show 6 more statements
What management expects
- The company expects most of its growth to come from improved field force productivity, with productivity reaching 4 to 4.5 lakhs in the next 3 years.
Show source
But having said that, I think getting it to 4 to 4.5 lakhs range in next 3 years is what is feasible.
- The company expects full-year growth to be higher than 12% to 14%.
Show source
Manish Gupta: No, this year, the organic growth will be higher than 14%, simply because last year's s econd half was terrible for us.
- The company remains on track to deliver its guidance for the current year while upping its margin expectations.
Show source
We continue to prioritise operational e fficiency, disciplined financial management, and long-term value creation and stay on track of delivering our guidance for the current year while upping the margin expectations.
- The company will see new launches in both derma and pedia going forward.
Show source
Of course, going forward, we will also see new launches in both derma and pedia.
- The company does not expect to repeat the Dydrogesterone scenario because it has no other mass molecule or mass market molecule in that context.
Show source
Page 18of 19 Jagsonpal Pharmaceutical Limited October 24, 202 4 So therefore, I don't think we'll have a repeat of that kind of scenario simply because other than Dydrogesterone, we do not have a mass molecule or mass market molecule in that context.
- The company typically looks at launching molecules below INR100 crores as part of its strategy for new products. Replaced by a later filing.
What it is building and selling
Demand and pricing
- The company faced hypercompetition in dydrogesterone and significant spurious product availability in its Indomethacin franchise around August/September 2023.
Show source
We faced hypercompetition in dydrogesterone, while our Indomethacin franchise saw significant spurious product availability.
Segments
- The dydrogesterone franchise became Jagsonpal Pharmaceuticals Limited’s largest product within 18 months of launch; Jagsonpal Pharmaceuticals Limited launched Dydrogesterone about 28 or 30 months ago, and it became very big.
Show source
This franchise had emerged as our largest product within 18 months of launch.
- The company was present in about INR10,000 crores worth of molecules, compared with the INR 220 lakh crore Indian pharmaceutical market covered by the CVM, as described on the call.
Show source
Jagsonpal was only present in about INR10,000 crores worth of molecules.
- The company covers about 80% of gynaecologists, 65% to 70% of orthopaedics, and a similar number in derma; Pedia coverage may be lower because Pedia is more spread out.
Show source
Manish Gupta: We cover about 80% of the gynaecologists.
- Strength is its medical representatives’ presence in doctors’ chambers, built through the company’s 40 years of operation.
Show source
What we really own or what is our strength is presence of medical rep in doctor's chamber, given that he has been visiting doctors for over 40 years.
- Core strategy is to pursue molecules sized below Rs 100 crores or less; Jagsonpal Pharmaceuticals Limited typically looks at launching molecules below INR100 crores as part of its strategy for new products.
Show source
And typically we look at launching sub-INR100 crores molecules.
Show 5 more statements
Segments
- The company has an asset-light model with complete outsourcing of its manufacturing requirement.
Show source
We have an asset-light model with complete outsourcing of our manufacturing requirement, with a robust QMS oversight.
- The company says Dydrogesterone was an exception to its strategy because the company undertook API development for it, and it was never expected to become a highly competitive molecule.
Show source
Now, Dydrogesterone was an exception for us as a strategy simply because of the API development that the company undertook, and it was never expected to become a highly competitive molecule.
- The company launched Dydrogesterone about 28 or 30 months ago, and it became very big. Replaced by a later filing.
- The company says its doctors have comfort and confidence in the quality systems, products and range of products it offers. Replaced by a later filing.
Show source
There is a fair bit of comfort and confidence on the quality systems, on the products and the kind of products that we offer to the doctor.
Deals and partners
- The company continues to source products from Yash Pharma's manufacturing setup under the transaction structure because the products are hormonal, while Pedia and Derma products are predominantly liquids and creams that cannot be manufactured at its other current third-party location.
Show source
So, the way the transaction is structured, we c ontinue to source from Yash Pharma's manufacturing setup.
Everything else said on the call
Group structure
- Infinity Holdings acquired a majority stake of 43%+ in Jagsonpal Pharmaceuticals Limited and became its promoters about 2 years before the call.
Show source
As some of you are aware, the company underwent a change of control about 2 years back when Infinity Holdings acquired a majority stake of 43%+ in the company and stepped in as promoters.
- The Kochhar family retained a 25% stake in Jagsonpal Pharmaceuticals Limited and stepped down from management responsibilities.
Show source
The erstwhile promoters – the Kochhar family, opted to retain a 25% stake, although they stepped down from management responsibilities.
- The company concluded its first acquisition, of the Yash Pharma business, in Q 1, expanding its therapeutic presence with the addition of dermatology and paediatrics.
Show source
We also concluded our first acquisition of Yash Pharma business in Q 1 which expanded our therapeutic presence with addition of dermatology and paediatrics.
- The company acquired the India and Bhutan business of Yash Pharma, which had sales of about INR48 crores last year and about 48 crores in the last 12 months, with a roughly 60-40 split between Derma and Pedia.
Show source
We have acquired the India and Bhutan business of Yash Pharma as was mentioned in stock exchange disclosures .
- The Yash Pharma business acquired by Jagsonpal Pharmaceuticals Limited had initial operating margins of about 12% when acquired.
Show source
That was the broad numbers as far as Yash Pharma business was concerned and their initial operating margins were in the region when we acquired, were in the region of about 12%.
- The company paid INR 94 crores to acquire the Yash Pharma business.
Show source
Manish Gupta: We paid INR 94 crores to acquire.
Show 5 more statements
Group structure
- Yash Pharma operates as a division of Jagsonpal Pharmaceuticals Limited, which acquired the business and not the company.
Show source
So, it operates as a division of the company and not anything more than that.
- The company says bankers approach it with acquisition opportunities, which it considers for strategic effect.
Show source
So there are bankers who keep knocking at us and we look at it if there is a strategic effect.
- The company says acquisition is constrained more by pricing than strategy; it prioritises potential brand acquisitions in its existing therapies over a business or new therapy acquisition because brand acquisitions offer the largest positive synergies, while prevailing market expectations make targets uneconomic.
Show source
So, priority-wise, it will be always a potential brand in the therapies that we are in, followed by business or new therapy.
People and governance
- The company added 30 to 40 people organically in the last three years and added about 220-240 medical reps through the Yash Pharma acquisition.
Show source
But I think a larger increase came out of Yash Pharma because about 220-240 odd medical reps got added through that acquisition.
- Harsha Raghavan from Infinity Holdings joined the Board of Jagsonpal Pharmaceuticals Limited as Chairman, and Debasis Nandy joined as chair of the Audit committee.
Show source
Consequent to the changes in the cap table, the Board was reconstituted with Harsha Raghavan from Infinity Holdings joining as Chairman of the Board, Debasis Nandy – CFO of Thomas Cook Group of companies joining as chair of the Audit committee.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Nirali Shah: Hi, congratulations on the strong result this quarter. So, Manish, I have two question. I had a couple of questions to begin with. On your recent launch of MemUp which is, I believe, the first bioidentical hormone, could you just elaborate on the market that you are targeting with this product and what kind of growth prospects and competition are you expecting in this segment?
Answer, manish gupta
Manish Gupta: So, Nirali your line was a little tough to handle in that sense, but I understand your question is on our recent launch of MemUp . Is that right?
Question
Nirali Shah: Yes sir. Page 4of 19 Jagsonpal Pharmaceutical Limited October 24, 202 4 Manish Gupta: So MemUp is the first hormone replacement therapy product or the first product in the country to deal with menopause because for whatever, unfortunately, this topic is not an area which has been fully understood by the doctors as well as the patient population.
Answer, manish gupta
They take it as a phase of life and while of course it is a phase of life, but the adverse mood swings and the other physical implications of menopause can be handled through these hormone repl acement therapies such as MemUp. So, we were the first ones to introduce. It's a long journey here, because we are working on creating an awareness both at the doctor level and patient level. And that's why you will see a lot of efforts are being put through our CSR initiatives under My Sakhi website wherein we are engaged with eminent doctors who are addressing and interacting with patients as also their fellow doctors on this subject every fortnight. So, it's a long journey. It's a concept -building product something that has not been there in this country. Numbers are very insignificant at this point of time, but I believe it's the need of this country, given that now we have a significant population a bove 45 years of age.
Question
Nirali Shah: Yes, I got clarity on that one. Second, I had a question regarding our CDMO business. So, how well are we prepared for the sector tailwinds that are coming in from the CDMO side and how are we trying to capitalize on these opportunities?
Answer, manish gupta
Manish Gupta: Nirali, we are not in CDMO business at all , we are a pure domestic pharmaceutical sales and marketing organization. We do not do any manufacturing, either for ourselves or for anybody else. So, CDMO is not part of our business model at all. Our intent is to leverage our strengths in India, which is a fairly interesting market. A nd there are significant opportunities to in-license products developed by global innovators who do not have presence in India. So, it will be a reverse for us. We are not into CDMO model at all.
Question
Nirali Shah: Okay, I guess I read in the IP that there is some kind of partnership in CDMO. So, got a little bit stuck there.
Answer, manish gupta
Manish Gupta: No, we partnered with CMOs for manufacturing of our products or CMOs and or CDMOs to develop and manufacture our products. So, it is the other way. It is only for our new initiatives. Like, MemUp was a product that was conceptualized at our end and thereafter we partnered with CDMO for developing it for us, for the Indian market.
Question
Nirali Shah: Okay, I understood. And last one on the profitability front. We have seen a very significant jump in EBITDA margins this quarter. So, if you could help understand what are the key drivers behind this margin expansion, what kind of margin trajectory are we expecting for the full year FY25 and the view going ahead for the next three to four years?
Answer, manish gupta
Manish Gupta: So, as you would have noticed in our outlook slide, which is the slide 23 of our investor deck, clearly, I mean, our margins are still below what industry delivers. We believe we have a fair bit of significant headroom that we can cover in the next couple of years. We have also offered guidance for the margins for the current year. Earlier, we were talking about 20% plus. Now, we are confident of 22% plus for sure. Difficult to predict the last number in the sense, in terms of Page 5of 19 Jagsonpal Pharmaceutical Limited October 24, 202 4 where we will end up. But we are fairly confident on improving our H1 margins in the current year for sure and delivering a 100 bps to 150 bps, if not more, margin expansion year on year over the next three years.
Question
Nirali Shah: Got it. Any specific reason, any specific segment that is contributing and which is the reason why we are seeing this jump or betterment in the margins?
Answer, manish gupta
Manish Gupta: It is simply better utilization of our field force. So, as the sales grows, majority of costs in domestic pharma are fixed given that they are related to the field force related expenses. Our gross margins in the business are fairly decent at about 65%, if not more. And therefore, our growth in sales, which is where we are guiding towards 12 % to 14%, will certainly lead to margin expansion as our costs do not go in proportion to that.
Question
Aman Saifee: Sir, could you help me with the Yash Pharma revenue and PAT number for this quarter?
Answer, manish gupta
Manish Gupta: Yash Pharma revenue and PAT ? See, Yash Pharma, we only acquired the business. We did not acquire the company. So, it operates as a division of the company and not anything more than that. Having said that, as I mentioned, if you look at our INR 74.7 crores sales, our core business without Yash Pharma grew by 5% for the current year and rest has been contributed. About INR14 crores out of that 74.7 is contributed by the Yash Pharma related division. We, of course, do not have divisional PMLs.
Answer, manish gupta
Manish Gupta: Aman, can you repeat your question, I could not fully understand.
Question
Aman Saifee: Sir, I was asking that our acquisition of the Yash Pharma has drive n this quarter's revenue and profitability. So, I wanted to understand, sir, why is our standalone business not really growing for the past two years?
Answer, manish gupta
Manish Gupta: This, I think, I addressed in the opening remarks that since last August or September, we had faced headwinds in two of our key products. Between these two products, they accounted for almost a third of our sales. Dydrogesterone franchise and Indomethacin, both had different issues. One had hyper -competition, and one, of course, we faced with spurious product availability in the country. So that really impacted our performance in the last 12 months. Both these issues are now behind us, and therefore, as I mentioned in my opening remarks, you see a recovery in our core business. We have grown 5% in our core business in this quarter, and this growth rate will now accelerate as we go forward.
Question
And can you please elaborate on the specific synergies you realized from acquisition of Yash Pharma, both operationally and financially? How are these expected to impact on the overall growth and margins in the near term?
Answer, manish gupta
Manish Gupta: Yes. So, historically, if you look at Jagsonpal , we were present in very narrow therapeutic area, even within gyna ecology and orthopaedics. So the CVM, as it is called, covered molecules in the entire INR 220 lakh crore s Indian pharmaceutical market. Jagsonpal was only present in about INR10,000 crores worth of molecules. Now, this strategy was fantastic because it gave us a very strong position in the areas we were in, but it limited our growth potential in some form. It was, therefore, important to expand our therapeutic coverage aligned with our stra tegy. So as a strategy, we want to stay in sub chronic segments.
Answer, manish gupta
By subchronic, our therapies or products that require consumption from between one month to a couple of months. So these are neither chronic, which are lifetime therapies, nor very acute, which are few weeks of therapies. These are subchronic therapies, and that's where Yash Pharma portfolio, which was in dermatology and paediatrics, was suitable to our strategy. It helps us expand our therapeutic marketplace. It was an under-managed business, so, therefore, we could see opportunities to synergize and creat e value out of it, and that's why we went ahead with that acquisition.
Question
Aman Saifee: Understood, sir. And, sir, given the rising competition in some of the key therapeutic areas, like Dydrogesterone, how does the company strategically position itself to maintain the market share? What are the steps we are taking in terms of maintaining our market share?
Answer, manish gupta
Manish Gupta: So Dydrogesterone is one unique example, and I think we can probably have a little longer offline discussion, but I will try to give you a very quick perspective. This is a molecule which had only Abbott as the sole player for many, many years, because of lack of availability of API. This is one of the very few photosynthetic APIs, which was first developed by Mankind, second by Emcure, and third by Jagsonpal. And these were the three ones to launch. All of the companies did well. Eventually, for some reason, the technology got leaked, and therefore, somewhere last year, we ended up with close to 80 players in the market, given that this molecule was almost a 1,000-pro molecule in India. That led to hyper -competition, and clearly, a lot of players suffered in the bargain.
Answer, manish gupta
I believe the market will now stabilize as some of the lesser players will go out, given that it is no longer profitable to be in this molecule with so many competitors. So things will only improve from here on. But for the time being, we are just maintaining ourselves, rather than being aggressive in this molecule. However, as I mentioned, this is an area of larger discussion, and I will be happy to take this offline with you.
Show 13 more questions
Question
So my first question is on our guidance of 12% to 14% top line growth over the medium term. So if you could please highlight, what are the key growth drivers for this? Is this going to be l argely organic? Are we planning to launch any new product introductions? And what would be the key therapy areas which would drive this growth?
Answer, manish gupta
Manish Gupta: Yes. So Neelam, thanks for joining in. And clearly the 12% to 14% guidance that we have given is the pure organic growth. Any inorganic growth, which is of course part of strategy, cannot be predicted and will be additional to what we have indicated. Now coming to what will drive this organic growth, as is the case with Indian pharmaceutical industry, fundamentally there are three growth levers. One is volume increase. Of course volume increase in the industry is slightly subdued for the last couple of years.
Answer, manish gupta
Second is price increase. And third is new products. So I believe the 12- 14% growth that we have been guiding to will be combination of the three with equal weightage for all of them. So I believe between 3% to 5% will be contributed by each of those. Of course some products will grow faster than the others. Our strategy around new products is linked to the therapeutic presence that we are in. And typically we look at launching sub-INR100 crores molecules.
Answer, manish gupta
So we actually do not go for large opportunities. We believe being a meaningful player in sub-INR100 cro res molecule or sub- INR100 crores opportunity is a far more manageable, profitable and sustainable area of opportunity. So that's the way we are going to work on. Fundamentally we are science-based company. We are not a pure commerce-driven organization in the doctor's chamber. We deal with the scientific requirements of the doctor. And I believe that the space which is le ss competitive, is little more difficult to crack.
Answer, manish gupta
So that is going to be also the way we choose our products. So you will see MemUp, which was the question asked by Nirali. It's a very conceptual product. It's going to be a slow grinding increase in sales. But I believe that will be for keeps for us. And similar is the strategy for all our new products or most of our new products. Does that answer, Neelam?
Question
Neelam Punjabi: Yes, sir. That's very helpful and quite elaborative. My second question is on our margins. So we have reached 25% margins this quarter. We are guiding for 22% for the whole year with 100, 150 basis points expansion going forward. So over the medium term, i f you could highlight, what is the peak potential margins that our business can reach?
Answer, manish gupta
Manish Gupta: So if you look at your domestic pharmaceutical businesses, most of them, once you have reasonable scale, operate at 30%-plus EBITDA margin. I think what we currently lack is that level of scale. But I believe in 3 years, we should be closer to 30%, if not breaching the mark.
Question
Neelam Punjabi: Okay. And if I look at our field force, we have about 900 plus MRs right now. So that means, as per Q2 numbers, our productivity stands at 2.8 lakhs . So whereas the industry operates, anywhere between 5 lakhs to 10 lakhs of productivity. So where do we see our number going forward? Page 8of 19 Jagsonpal Pharmaceutical Limited October 24, 202 4 Manish Gupta: Yes.
Answer, manish gupta
So this is a very, very good question, Neelam. Fundamentally, the reason for guiding towards a margin expansion is actually coming from this only. So we believe in the current field force, we have all the coverage that is needed. So most of our growth wi ll actually come from improved field force productivity. The nature of the product that we have will not allow us to get that 5 lakhs and 10 lakhs PCPMs that some of the better companies or bigger companies can command. Because as I mentioned, our strategy is to look after smaller niche molecules. But having said that, I think getting it to 4 to 4.5 lakhs range in next 3 years is what is feasible.
Answer, manish gupta
And that should translate into the guidance that we are giving.
Question
Neelam Punjabi: Okay. And lastly, my question is on the cash balance of about INR93 crores in our balance sheet right now? So could you outline your capital allocation strategy? How much of this cash is your mark for potential acquisitions versus reinvestment in our business?
Answer, manish gupta
Manish Gupta: So our model is such that we actually do not require investments by itself in the business. In fact, our cash to EBITDA conversion has been close to 100% or 103% over last five years. I think there were opportunities to reduce our working capital. Most of that is over. But net of tax leakage, everything else will be converted to cash for us. So our business requirements are limited as far as strategies are concerned. So all of this cash and whatever we generate even going forward will be used for inorganic strategies only.
Question
Neelam Punjabi: And lastly, if you can just highlight the strategy around inorganic and acquisitions going forward, what are we looking for there?
Answer, manish gupta
Manish Gupta: This is a difficult one because acquisitions are 60% strategy and 40% opportunity. So there are clearly -- there will be two sets of acquisitions we will be looking at. One is if we can penetrate deeper in the therapies that we already have. So if there are opportunities to acquire brands in the four therapies that we are already in will be one part of our strategy. And second would be to expand into newer therapies which will be more like a business acquisition because that's where we will need separate field force like we did in the case of Yash Pharma. So it will be a two-pronged acquisition strategy. Brands within the therapies we are in or businesses with field force if we were to get into additional therapies.
Answer, manish gupta
But our therapy choice will be sub-chronic. We shall not get into both acute and or chronic segments.
Question
Neelam Punjabi: Got it, this is very helpful and that’s all from my end. All the very best.
Answer, manish gupta
But having said that, Infinity Holdings is a private equity organization. It's a perpetual fund unlike time frame funds which most PEs are, which means typically they invest, they do not have a time frame for investment. And they believe in compounding stories, which is where Jagsonpal fits very, very well for them. This is their first and the only pharmaceutical investment. However, they are of course invested in many other industries like Hindustan Foods and they have also Fly91, which into airline industry. You can get more information on their company through their website Convergent Finance. In terms of management changes, I think the operating teams remain largely the same.
Question
Anupam Agrawal: Thank you so much for the opportunity and congratulations sir, on a great set of numbers. My first question is sir in the first half of INR 136 crores of top-line, can you bifurcate between the therapies that we are presenting across the four segments?
Answer, manish gupta
Manish Gupta: Yes, I don't have perfect numbers, but I'll give you reasonably accurate numbers in that sense. 50% of our sales would be in the space of gyna ecology. Another 20% odd will be in ortho and between Derma and P edia would be the rest of the sales splitting almost equally.
Question
Anupam Agrawal: Okay. Understood. So, going forward 3 to 5 years what and how do you see the split across therapies going forward? I mean, if you can also call out the number of products that are in the pipeline, what are we looking at in terms of launches going forward?
Answer, manish gupta
Manish Gupta: We cover about 80% of the gynaecologists. We cover about 65 % to 70% of the orthopaedics. Of course, the numbers in derma would be again similar. Pedia may be a little lower because Pedia is more spread out in that sense. I don't think we need to change or increase our doctor coverage in terms of percentages. But we need to improve our doctor choice. And that's an exercise we are undertaking at this point of time.
Answer, manish gupta
I come from a purely regulated market background and therefore, for me, quality is first, which was also a shared perspective with the erstwhile promoters. So, that gave us the confidence that we do all the right things in ensuring quality. Yash Pharma business, which we have just acquired, Yash was a manufacturing organization and also they had export business. So, the way the transaction is structured, we c ontinue to source from Yash Pharma's manufacturing setup. It cannot be manufactured at our current other third-party location, simply because the nature of products are very different. One is hormonal and this is liquids and creams predominantly in the, both the Pedia and Derma are liquids and creams fundamentally.
Answer, manish gupta
Manish Gupta: Yes. So, we have not acquired the company. We have acquired the India and Bhutan business of Yash Pharma as was mentioned in stock exchange disclosures . I think the company did about INR48 crores of sales last year. When I say company, I mean the business. The business that we acquired had about 48 crores worth of sales in last 12 months. Roughly 60- 40 split between Derma and Pedia .
Answer, manish gupta
That was the broad numbers as far as Yash Pharma business was concerned and their initial operating margins were in the region when we acquired, were in the region of about 12%. This is based on what we have disclosed and what was the diligence information.
Question
Alisha Mahawla: And what did we pay to acquire this?
Answer, manish gupta
Manish Gupta: We paid INR 94 crores to acquire.
Question
Alisha Mahawla: And what kind of MR addition have we done in the last three years?
Answer, manish gupta
Manish Gupta: Organically, 30 to 40 people in the last three years. But I think a larger increase came out of Yash Pharma because about 220-240 odd medical reps got added through that acquisition.
Question
Alisha Mahawla: What kind of product launches we would have done in the last three years?
Answer, manish gupta
Manish Gupta: Within the therapies that we are in, we have made like Dydrogesterone was a new launch about 28 or 30 months back, which became very big. So, it is all within the therapies predominantly in gynecology that we have done in last three years. Of course, going forward, we will also see new launches in both derma and pedia.
Question
Milan Shah: Good morning, sir. Thank you for the very insightful and transparent discussion that you are conducting. My question is about the competitive mode of the company, because you mentioned that we do not want to manufacture any molecule. More or less, it is a kind of a trading company. So, what is our USP which others would not be able to replicate?
Answer, manish gupta
That's why, if you recollect, the manufacturing kept swinging from Daman to Goa to Badri and then to Sikkim and now to Jammu. So, manufacturing dynamics for India are very different from global manufacturing dynamics. And I don't think manufacturing is any competitive advantage in the Indian context. What we really own or what is our strength is presence of medical rep in doctor's chamber, given that he has been visiting doctors for over 40 years. I am not suggesting that people have been around for 40 years, but the company has been around for 40 years. There is a fair bit of comfort and confidence on the quality systems, on the products and the kind of products that we offer to the doctor. So, it' s really our ownership of the doctor's chamber that we are good at.
Question
Sriram R: Thank you so much. All the best.
Answer, manish gupta
Manish Gupta: In the first half, our organic growth is 2%, between 2% and 2.5%. Largely driven by 5% growth in Q2, because if you recollect, our Q1 was almost flat. Raaj: Okay, So we are expecting full year organic growth of 12% to 14%, right?
Answer, manish gupta
Manish Gupta: No, this year, the organic growth will be higher than 14%, simply because last year's s econd half was terrible for us. I won't claim it. We have done a great job. That full year growth will be higher than 12% to 14%. It's just that the base for second half is not too good. Raaj: Alright And sir, you have also directed for 22% plus EBITDA, right?
Answer, manish gupta
Manish Gupta: That's correct. Raaj: And this EBITDA margin is expected to increase 1 to 1.5% year on year for at least next 3 to 4 years.
Answer, manish gupta
Everyone knows we are sitting on cash. Everyone knows our s trategic intent of acquisition. And in the scale that we are in, actually, we do not have much competition. In our country, either there are big buyers, likes of Torr ent and Mankind and what not. But in the space that we are in, I think there is not much competition. So there are bankers who keep knocking at us and we look at it if there is a strategic effect. Page 16of 19 Jagsonpal Pharmaceutical Limited October 24, 202 4 Raaj: And sir, the sales per MR is around 2.8 lakhs per month per MR. Around that figure, right?
Answer, manish gupta
How will you reach 4.5 lakhs in next 3 years' time? Because if I look at the coverage, the coverage is pretty much fine. It's around 85% in Gynac and 56% Pedia. So I wanted to understand what strategy are you planning to adopt to increase the sales per MR?
Answer, manish gupta
Manish Gupta: Difficult question. I think all three are focus areas, but I think the challenge in acquisition is more pricing than strategy. And strategy-wise, clearly, I think the largest positive synergies always comes from brand acquisition rather than business acquisition. Okay. So, priority-wise, it will be always a potential brand in the therapies that we are in, followed by business or new therapy. But I think what constraints is the pricing environment currently prevalent in the market. Expectations are so high that it simply doesn't make sense to acquire any of those targets.
Answer, manish gupta
Manish Gupta: No. So our core strategy, as I mentioned, is always to go for sub-100 crores or lesser-sized molecules. Now, Dydrogesterone was an exception for us as a strategy simply because of the API development that the company undertook, and it was never expected to become a highly competitive molecule. Page 18of 19 Jagsonpal Pharmaceutical Limited October 24, 202 4 So therefore, I don't think we'll have a repeat of that kind of scenario simply because other than Dydrogesterone, we do not have a mass molecule or mass market molecule in that context. Having said that, again, this question, I mean, because it relates to a lot to our strategy, I think I would be happy to take it offline given that it will require a much longer answer. Saket: Sure, sure, Manish. I appreciate your transparency and maybe looking forward to connecting with you sometime. Thank you.
Questions about this call
- When was the Jagsonpal Pharmaceuticals Q2 FY25 earnings call transcript filed?
- Jagsonpal Pharmaceuticals filed the transcript with the exchange on 29 Oct 2024. This page is built from that transcript.
- What does this page list?
- 50 statements from the transcript across 8 topics, 37 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 23 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.